In Type II diabetic patients, dual antiplatelet therapy is indicated for the primary prevention of cardiovascular and cerebrovascular events, which is commonly composed of low dose aspirin and other antiplatelet agents. This increases the risk of esophageal lesions, gastroduodenal ulcers and bleeding. Contrary to common belief enteric coated aspirin or buffered varieties are no more safer than the plain aspirin. We present a case of an elderly patient who developed adverse events that were associated with the low dose enteric coated aspirin. Patient‘s prognosis improved dramatically after the drug was withdrawn. Based on these findings, we argue for the need to assess the risk of gastrointestinal mucosal injury and hemorrhage in cases where LDA therapy is entailed.